StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3072% below fair value
$5.79−0.10 (-1.70%)

Close on Nov 13, 2026Market cap $296.87MP/E –Yield –

Emergent BioSolutions price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Emergent BioSolutions's price to sales ratio was 0.4× on Nov 11, 2026, against 0.7× a year earlier. Over the last 5 years it ranged from 0.1× to 1.5×, with a median of 0.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.4×−0.4
2025Dec 31, 20250.8×+0.4
2024Dec 31, 20240.5×+0.3
2023Dec 29, 20230.1×−0.3
2022Dec 30, 20220.4×−1.1
2021Dec 31, 20211.4×−2.1
2020Dec 31, 20203.6×+0.8
2019Dec 31, 20192.7×−1.5
2018Dec 31, 20184.2×+0.5
2017Dec 29, 20173.7×+1.0
2016Dec 30, 20162.7×−0.6
2015Dec 31, 20153.3×+0.7
2014Dec 31, 20142.6×−0.4
2013Dec 31, 20133.0×+0.9
2012Dec 31, 20122.0×−0.2
2011Dec 30, 20112.2×−0.9
2010Dec 31, 20103.1×–

More Emergent BioSolutions figures

See a number that looks wrong?